
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Holdings Inc. is demonstrating a strong positive trajectory due to the attainment of RMAT designation for its lead gene therapy candidate, detalimogene, which enhances its market potential, especially in community practice settings. The company's clinical trial results indicate that detalimogene's six-month complete response (CR) rate aligns with leading therapies while benefiting from a preferable non-viral delivery method, thus expanding its potential addressable market. Additionally, the marked increase in research and development expenditures reflects significant investments in advancing their pivotal LEGEND study, contributing to an elevated discounted cash flow-derived valuation estimate.
Bears say
enGene Holdings Inc faces several challenges that contribute to a negative outlook on its stock. The company is experiencing disappointing performance in its LEGEND trial for detalimogene, alongside unexpected safety issues and changing regulatory requirements that could delay approvals, ultimately impacting investor confidence and share price. Additionally, the heightened competition and anticipated need for further equity financing pose significant financial risks, potentially resulting in dilution for existing shareholders.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares